Employee ownership culture with endpoint-oriented management

Employees are encouraged to meet the clients' needs and drive the business from small to big, from less to more, from simple to complicated, from passive to proactive

Taiping Chen, DVM, Ph.D.

Founder and Chief Executive Officer

For the last decade, Dr. Chen has dedicated himself within the CRO industry to providing world class services to countless drug discovery clients. His many clients come from diverse areas all across the world, ranging from the largest and most premier pharma companies, to hundreds of specialized and independent biotech companies. Dr. Chen’s passion for the future of oncology, is reflected by the brilliant and ambitious team that has assembled around him, eager to explore the challenges and possibilities of their clients needs.

During his tenures as the CSO and Vice President of LIDE Biotech, Viva Biotech, and Crownbio, he pioneered a number of movements within the industry, including the development of Translational Oncology. Under his direction at Crownbio, the small and unremarkable translational oncology team grew into a vital department of well over a hundred scientist dedicated to providing complicated and high quality services like CDX, PDX (solid and leukemia) pharmacology, genomic and biomarker profiling platforms.

In addition to his extensive leadership experience with CRO, Dr. Chen spent years as a biomarker group leader at ArQule, providing critical support at preclinical and clinical stages, and working heavily to shoulder the company's many drug programs. Prior to ArQule, he was Associate Director for the better part of a decade at Wood Hudson Cancer Research Lab where he dedicated himself to clinical biomarkers studies and research in conjunction with Lilly’s target validation team.

Dr. Chen received his DVM equivalent in Veterinary School, Shanxi Agricultural University in China. He received M.S. degree of Immunology at the National Control Center of Veterinary Medicine, Beijing, China. He earned his Ph.D. in Cancer Genetics from University of Texas MD Anderson Cancer Center and completed his postdoctoral research at Yale University School of Medicine. Chen has authored more than 60 abstracts and publications.

To provide key efficacy data on the new drug development and biomarker exploration of translational pharmacology for our clients